West Chester-based Verrica Pharmaceuticals is releasing new clinical data showing its molluscum treatment works whether a patient was diagnosed weeks ago or over a year ago.

A pooled analysis of two Phase 3 trials found that 58.8% of patients who had molluscum contagiosum for more than 12 months achieved complete lesion clearance after YCANTH treatment, compared with 5% who received a vehicle placebo, according to a company announcement on Sept. 10. Among patients diagnosed within 12 months, 48.9% cleared completely versus 16.7% on placebo. Both results were statistically significant.

CEO Jayson Rieger called the findings "particularly meaningful" because they challenge a wait-and-watch approach that was common before YCANTH became the first FDA-approved treatment for molluscum. The disease affects an estimated six million Americans annually, mostly children, according to the company.

YCANTH (VP-102) is a drug-device combination containing a controlled formulation of cantharidin delivered via a single-use applicator. It is approved for patients two years and older.

"For YCANTH, knowing that there is a robust treatment effect regardless of how long a patient has had molluscum gives clinicians confidence to treat their patients with YCANTH at any time after diagnosis," Chief Medical Officer Noah Rosenberg said in the announcement.

The data are being presented for the first time at two dermatology conferences: Maui Derm NP+PA Fall 2026, running Sept. 16–19 in White Sulphur Springs, W.Va., and the 27th Annual Las Vegas Dermatology Seminar, running Sept. 17–20 in Las Vegas.

Cancer drug data re-presented

Verrica is also re-presenting Phase 2 findings for VP-315, an experimental therapy for basal cell carcinoma, first shown at the 2026 Society for Investigative Dermatology Annual Meeting. In an exploratory analysis, investigators injected VP-315 directly into target tumors and then tracked 14 separate, untreated lesions on the same patients. Those untreated lesions shrank on average, and three of the 14 achieved complete histological clearance.

The company described the response as "abscopal-like activity," suggesting the localized injection may trigger a broader immune response. Verrica calls VP-315 a potential first-in-class treatment, though no Phase 3 timeline has been announced.

Commercial momentum

The clinical presentations come as YCANTH demand grows. Rieger said on Aug. 13, when the company reported Q2 2026 earnings, that "demand for YCANTH continues to accelerate." Verrica dispensed a record 19,626 applicator units in the quarter ending June 30, up 46.1% year over year. U.S. net product revenue rose 12.3% to $5.1 million in that period.

YCANTH is also approved in Japan and is being studied in a global Phase 3 program for common warts.